Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Henlius Biotech, Inc. has announced that its application for the clinical trial of HLX17, a pembrolizumab biosimilar for treating various cancers, has been approved by the National Medical Products Administration. HLX17, which mimics the original drug pembrolizumab, has shown similar preclinical pharmacologic properties and could potentially offer alternative treatment options for multiple cancer types. However, the company cautions that the development and commercialization of HLX17 are not guaranteed and advises shareholders and potential investors to trade with caution.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.